Innate Pharma S.A.
NASDAQ:IPHA · NASDAQ Global Select
+$0.03 today
Vol 0.00M · Avg 0.07M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+0.56%
Period High
$2.38
Period Low
$1.17
Latest
$1.81
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Nuvectis Pharma, Inc.
NASDAQ:NVCT
$345.63M
Compugen Ltd.
NASDAQ:CGEN
$188.63M
Molecular Partners AG
NASDAQ:MOLN
$146.29M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$112.08M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.29M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$82.39M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$72.01M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$50.82M
Applied Therapeutics, Inc.
APLT
$14.86M
What is the latest IPHA filing?
The latest filing shown is 6-K dated May 22, 2026.
How many recent filings does IPHA have?
Intrinsic Alpha currently shows 20 recent filings for IPHA.
Explore More
Continue the stock analysis
Jump to another research area for this company.